Document is current
Any future updates will be listed below
-
Authors
Reisch, Myriam https://orcid.org/0009-0003-3578-8205
Thiel, Jens https://orcid.org/0000-0001-7582-1514
Bosch, Philipp https://orcid.org/0000-0002-6783-6422
-
Funding
Funding for this research was provided by:
Medical University of Graz
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 12 April 2026
First Online: 4 May 2026
Declarations
:
: MR: Consultancy: Lilly; Adboard/speaker fees: Alfasigma, Novartis. JT: Consultancy: AbbVie, Janssen, Lilly, Novartis, CSL Behring/Vifor, GSK, AstraZeneca; Speaker Honoraria: AbbVie, Galapagos, Janssen, BMS, Lilly, Vifor, StreamedUp, CSL Behring/Vifor, GSK, AstraZeneca; Research funding: BMS, GSK; Patent application: Pending patent application for the use of secukinumab in GCA. PB: Adboard/speaker fees by Johnsson and Johnsson, AbbVie, Lilly and UCB, Novartis; Project grants: Pfizer.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable
: Not applicable.
: MR performed the literature search and drafted the manuscript. JT and PB reviewed the content critically for intellectual input and revised the manuscript. All authors read and approved the final manuscript.
